Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis

Journal of Clinical Pharmacology

Volumn 50, Issue 3, 2010, Pages 257-267

  Zhou, Honghui ^a   Hu, Chuanpu ^a   Zhu, Yaowei ^a   Lu, Ming ^a   Liao, Sam ^b   Yeilding, Newman ^a   Davis, Hugh M ^a  

^a CENTOCOR INC   (United States)

^b Pharmax Research Inc   (United States)

Author keywords

Exposure response; Interleukin 12 23p40; Monoclonal antibody; NONMEM; Pharmacodynamic modeling; Population pharmacokinetic; Psoriasis; Ustekinumab

Indexed keywords

CYCLOSPORIN; METHOTREXATE; USTEKINUMAB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; MULTICENTER STUDY; PLACEBO EFFECT; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; PLACEBO EFFECT; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77649209264     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009343695     Document Type: Article

References (21)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996 ; 14: 485-496.
2. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol. 1994 ; 102: 14S - 18S.
3. Schon MP, Boehncke WH Psoriasis. N Engl J Med. 2005 ; 352: 1899-1912.
4. Gottlieb AB, Chao C., Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008 ; 19: 5-21.
5. Chan JR, Blumenschein W., Murphy E., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006 ; 203: 2577-2587.
6. Langrish CL, Chen Y., Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005 ; 201: 233-240.
7. Yawalkar N., Karlen S., Hunger R., Brand CU, Braathen LR Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol. 1998 ; 111: 1053-1057.
8. Rozenblit M., Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. 2009 ; 22: 56-60.
9. Mascelli MA, Zhou H., Sweet R., et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007 ; 47: 553-565.
10. Zhu Y., Hu C., Lu M., et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009 ; 49: 162-175.
11. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 ; 371: 1665-1674.
12. Papp KA, Langley RG, Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 ; 371: 1675-1684.
13. Menter MA, Krueger GC, Feldman SR, Weinstein GD Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol. 2003 ; 49: S39 - S43.
14. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999 ; 141: 185-191.
15. Geng D., Shankar G., Schantz A., Rajadhyaksha M., Davis H., Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal. 2005 ; 39: 364-375.
16. Byon W., Fletcher CV, Brundage RC Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn. 2008 ; 35: 101-116.
17. Krzyzanski W., Jusko WJ Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci. 1998 ; 87: 67-72. (Pubitemid 28079263)
18. Zhu YW, Yeilding N., Guzzo C., Marini J., Mascelli MA, Davis H. Pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation of CNTO 1275 in subjects with moderate to severe psoriasis vulgaris. J Clin Pharmacol. 2007 ; 47: 1203.
19. Savic R., Wilkins J., Karlsson MO (Un)informativeness of empirical Bayes estimate-based diagnostics. AAPS J. 2006 ; 8: T3360.
20. Hu C., Zhou H. An improved approach for confirmatory phase III population pharmacokinetic analysis. J Clin Pharmacol. 2008 ; 48: 812-822.
21. Zhang L., Beal SL, Sheiner LB Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003 ; 30: 387-404. (Pubitemid 38221931)